Cencora Inc. (COR) exhibits 3.6% gross margins and 26.8% return on invested capital within Health Care (Other Pharmaceuticals), balanced against a 21.6x enterprise multiple and 4.8% implied options volatility.
Sustained 3.6% gross profitability converts into 0.8% operating margin and 26.8% ROIC, outpacing sector cost of capital.
ROIC: 26.8% // GM: 3.6%YoY revenue trajectory of +9.3% paired with 5.08% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +9.3% // FCF YLD: 5.08%Altman Z-Score of 5.27 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 5.27 // F-SCORE: 6/9Trading at 40.6x trailing P/E (37.8x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 40.6x // EV/EBITDA: 21.6xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $330.84 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Other Pharmaceuticals require continuous execution to defend 0.5% net margins.
NET MARGIN: 0.5% // D/E: 3.97x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for COR & activate live FRED threshold breach alerts.